This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from an acute exacerbation of chronic bronchitis and take at least one dose of Moxifloxacin injection.The primary objective is to obtain clinical effectiveness and safety data of Moxifloxacin injection in the treatment of acute exacerbations of chronic bronchitis in patients in whom Moxifloxacin was routinely prescribed. The secondary objective is to find out the possible correlation between the risk factors (sex, smoking, number of previous exacerbations, etc) and AECB, the different treatment effectiveness according to Anthonisen classification. This study will also collect the data of pathogens by sputum culture and the defervescence time of Moxifloxacin injection in treating Acute Exacerbations of Chronic Bronchitis (AECB).
Study Type
OBSERVATIONAL
Enrollment
1,206
Patients from the normal praxis routine, treated with Moxifloxacin injection with/without sequential tablet treatment according to the local product information
Unnamed facility
Many Locations, China
clinical cure rate:clinical cure was defined as disappearance of acute signs and symptoms
Time frame: up to 21 days
Time to cure: time when symptoms are disappeared after Moxifloxacin treatment
Time frame: up to 21 days
Improvement time: time when patients feel improvemen
Time frame: up to 21 days
Time of patients recover from fever
Time frame: up to 21 days
Clinical efficacy rate of Moxifloxacin
Time frame: up to 21 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.